FOXC2 and colorectal cancer: FOXC2 fosters oxaliplatin resistance in colorectal cancer by triggering epithelial-mesenchymal transition through MAPK/ERK signaling.13 Insulin has been ascertained by previous studies to affect the expression of FOXC2.